Whalesbook
Financial Deep Dive
HealthCare Global Enterprises Limited (HCG) is set to convene its Board of Directors meeting on February 24, 2026, to iron out the specifics of a significant Rights Issue. This capital raising exercise aims to bring in up to ₹42,500 Lakhs, or ₹425 Crores, to bolster the company's finances. The meeting will determine key aspects such as the issue price, the ratio at which existing shareholders can subscribe for new shares, the record date to identify eligible shareholders, and the payment process.
The Numbers:
While the immediate focus is on the Rights Issue, HCG's financial health has been a subject of ongoing scrutiny. In the fiscal year ending March 2024, the company reported revenues of ₹19,079 million, a healthy 12.8% increase year-on-year (YoY). Its net profit also saw a substantial jump of 134.5% YoY to ₹413 million, with net profit margins improving to 2.2% from 1.0% in the previous year. However, more recent quarterly results have shown mixed performance. For Q3 FY25-26, one report indicated a net loss of ₹9.43 Crores and a negative net profit margin of -1.48% [6]. Another stated a Q3 FY25-26 net profit of ₹3.24 Crores, a significant YoY decline of 53.58% [7].
The Quality:
HCG's balance sheet carries a notable debt burden. As of March 31, 2025, its net debt had risen to ₹1,601 Crores, up from ₹1,001.75 Crores the previous year, driven by capital expenditure and acquisitions [2]. The company's debt-to-equity ratio is considered high, standing at approximately 177.9% according to one analysis [1], and has increased over the past five years [1]. This elevated leverage leads to a low interest coverage ratio, reported at just 1.4 times by EBIT [1], indicating a limited cushion to service its interest expenses [13]. Despite efforts to improve profitability, with EBITDA margins hovering around 17-18%, the rising debt levels and recent quarterly losses present financial challenges [2, 13]. The planned Rights Issue is expected to help strengthen the balance sheet, potentially by reducing debt or funding future expansion.
Risks & Outlook
Specific Risks:
The primary risk for HCG revolves around its substantial debt. The low interest coverage ratio signifies potential financial strain if earnings falter. A Rights Issue, while providing capital, can also dilute existing shareholders' stakes if they do not participate. Furthermore, recent analyst reports have highlighted concerns about deteriorating quality metrics and financial performance, leading to downgrades for the stock [13]. A significant development is the impending acquisition of a controlling stake by KKR from CVC Capital, which is expected to reshape the ownership structure and strategic direction [20, 35]. This transition could influence how the raised capital is deployed.
Negative History / Concerns:
While no instances of fraud or explicit SEBI penalties were found in the provided information, HCG faces significant headwinds related to its financial structure. The company's high debt-to-equity ratio, increasing gearing, and recent periods of negative profitability are considerable concerns for investors. Furthermore, a MarketsMojo report from February 2026 downgraded HCG to 'Sell' due to these weak fundamentals and elevated debt levels [13]. High promoter share pledging, reported at 85.23% as of February 2026, is also a risk factor that investors need to monitor [14].
The Forward View:
The success of the Rights Issue will be crucial for HCG's future growth trajectory. The raised funds are likely earmarked for expansion, debt reduction, or a combination of both, aligning with the company's strategy to capitalize on the growing demand for cancer care in India. The company plans to add approximately 900 incremental beds over the next 4 to 5 years [9]. Investors will closely watch how the new ownership under KKR integrates with the existing management and how effectively the company utilizes the new capital to drive sustainable profitability and reduce its financial leverage.
Peer Comparison
Apollo Hospitals Enterprises has demonstrated strong revenue growth, with a 17% YoY increase in Q3 FY26, and a substantial profit surge of 35% YoY. However, it trades at a high Price-to-Earnings (P/E) ratio of approximately 60-68 times [36]. Fortis Healthcare has also shown strong performance, with some comparisons indicating better long-term stock growth for HCG. Fortis also commands a higher P/E ratio compared to HCG, though recent reports suggest HCG's overall valuation might be more attractive relative to peers despite its profit declines [13, 23]. Aster DM Healthcare is another key competitor with whom HCG's performance is often benchmarked [22, 25, 42]. HCG's promoter holding stands at a robust 63.8%, higher than Apollo Hospitals (28%) and Fortis Healthcare (31.2%) [21, 41]. Despite recent financial headwinds, HCG's stock has exhibited strong long-term compounded annual growth rates (CAGRs) [21, 41].